Previous 10 | Next 10 |
2023-03-06 17:35:22 ET Zymeworks ( NASDAQ: ZYME ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, after market close. The consensus EPS Estimate is $3.11 (+414.1% Y/Y) and the consensus Revenue Estimate is $214.33M (+978.7% Y/Y). Over the last 2 yea...
Summary Jazz Pharmaceuticals, which is known for its Oxybate drug line used to treat narcolepsy, is seeking to diversify its product portfolio beyond Oxybate in anticipation of a revenue decline. After encouraging preliminary data for the treatment of first-line metastatic, HER2+ gastro...
Summary Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response. Zanidatamab is now Jazz's responsibility and Zymeworks stands to benefit as the program moves forward. Wit...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7 th , 2023. Following the announcement, man...
The following slide deck was published by Zymeworks Inc. in conjunction with this event. For further details see: Zymeworks (ZYME) presents at SVB Securities Global Biopharma Conference - Slideshow
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma PR Newswire Results presented today at ASCO GI include first overall survival (OS) data...
Summary Two new Breakout Stocks for Week 3 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +21.37% YTD. This week 2 of 4 high-frequency breakout picks gained over 10% in less than a week with peak gains in VYGR +66.1%, RES +13.0%, LTR...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...
The shares of cancer-focused biopharma Zymeworks ( NASDAQ: ZYME ) added ~13% on Friday to reach the highest level since late January 2021 after San Francisco-based biotech fund EcoR1 Capital, LLC raised its stake in the company. According to an SEC filing on Thursday, EcoR1 has pu...
Summary Last month, ZYME presented strong data in HER2+ BTC. Its Jazz collaboration has given it access to a lot of funds. The stock is still stagnant, probably because the market feels ZYME lacks growth prospects. For further details see: Zymeworks: Good D...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...